Evaluation of Behavior, Executive Function, Neurotransmitter Function and Genomic Expression Kuvan Nonresponders

CompletedOBSERVATIONAL
Enrollment

21

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
PhenylketonuriaBehavior and Behavior MechanismsPAH Gene Expression
Interventions
DRUG

sapropterin dihydrochloride

"In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.~Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted."

Trial Locations (1)

70112

Tulane University Health Science Center, New Orleans

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

BioMarin Pharmaceutical

INDUSTRY

lead

Tulane University School of Medicine

OTHER